Prelude Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Prelude Therapeutics Incorporated

10/08/2022 13:30

* Prelude Therapeutics Inc  PRLD.OQ  reported a quarterly
adjusted
loss of 58 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 61 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Prelude Therapeutics Inc's reported EPS for the quarter
was a
loss of 58 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Prelude Therapeutics Inc shares had risen by 24.7% this
quarter and lost 47.7% so far this year.
    * The company reported a quarterly loss of $27.37 million.
    * Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $9.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 12:30 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.61          -0.58          Beat
 Mar. 31 2022      -0.65          -0.63          Beat
 Dec. 31 2021      -0.68          -0.71          Missed
 Sep. 30 2021      -0.62          -0.66          Missed